Performance
5 Days
-0.19%
1 Month
26.14%
3 Months
14.60%
6 Months
353.45%
1 Year
267.83%
2 Year
-59.60%
Key data
Stock price
$23.75
DAY RANGE
N/A - $23.75
52 WEEK RANGE
$0.97 - $5.59
52 WEEK CHANGE
$2.68
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO:
Region: US
Website: imaratx.com
Employees: 41
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry:
Sector:
Region: US
Website: imaratx.com
Employees: 41
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry:
Sector:
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia.
Recent news